APA (7th ed.) Citation

Powell, M., Roed, H., Gilbert, L., Zub, O., McCourt, C., Fleming, E., . . . Mirza, M. (2025). 1113P Post hoc survival outcomes based on initial and subsequent treatment in patients (pts) with mismatch repair proficient/microsatellite stable (MMRp/MSS) primary advanced or recurrent endometrial cancer (pA/R EC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. Annals of Oncology, 36, S740. https://doi.org/10.1016/j.annonc.2025.08.1750

Chicago Style (17th ed.) Citation

Powell, M.A, et al. "1113P Post Hoc Survival Outcomes Based on Initial and Subsequent Treatment in Patients (pts) with Mismatch Repair Proficient/microsatellite Stable (MMRp/MSS) Primary Advanced or Recurrent Endometrial Cancer (pA/R EC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial." Annals of Oncology 36 (2025): S740. https://doi.org/10.1016/j.annonc.2025.08.1750.

MLA (9th ed.) Citation

Powell, M.A, et al. "1113P Post Hoc Survival Outcomes Based on Initial and Subsequent Treatment in Patients (pts) with Mismatch Repair Proficient/microsatellite Stable (MMRp/MSS) Primary Advanced or Recurrent Endometrial Cancer (pA/R EC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial." Annals of Oncology, vol. 36, 2025, p. S740, https://doi.org/10.1016/j.annonc.2025.08.1750.